Daniel Dewolf

Jan 15, 2025 | mondaq.com | Daniel Dewolf |Samuel Effron

As we turn our thoughts to 2025, there is clearly significantenthusiasm in the financial world for a bust-out year in venturecapital. Anecdotally, we can readily see that the number oftransactions is increasing, and perhaps we are witnessing aparadigm change with a new robust market for private companyfinancings. Hopefully, the dam holding back IPOs will break in2025. Deal flow is definitely increasing, especially with respectto any enterprise related to AI.

Jan 13, 2025 | jdsupra.com | Daniel Dewolf |Samuel Effron

As we turn our thoughts to 2025, there is clearly significant enthusiasm in the financial world for a bust-out year in venture capital. Anecdotally, we can readily see that the number of transactions is increasing, and perhaps we are witnessing a paradigm change with a new robust market for private company financings. Hopefully, the dam holding back IPOs will break in 2025. Deal flow is definitely increasing, especially with respect to any enterprise related to AI.

Jan 13, 2025 | mondaq.com | Daniel Dewolf |Samuel Effron

Surgimatix, our client spotlight this month, developed what canonly be called a novel solution. Surgimatix is an early-stagemedical device company pioneering the first proprietarylaparoscopic device that delivers suture-like fixation inseconds. Suturing is the gold standard for fixation of tissue in surgicalprocedures. For procedures performed laparoscopically, however,suturing is very difficult.

Jan 9, 2025 | jdsupra.com | Daniel Dewolf |Samuel Effron

Surgimatix, our client spotlight this month, developed what can only be called a novel solution. Surgimatix is an early-stage medical device company pioneering the first proprietary laparoscopic device that delivers suture-like fixation in seconds. Suturing is the gold standard for fixation of tissue in surgical procedures. For procedures performed laparoscopically, however, suturing is very difficult.

Sep 30, 2024 | mondaq.com | Daniel Dewolf |Samuel Effron |Jeremy Glaser

Although the emerging company market has been relatively depressed due to the downward pressure of a repricing environment, the Mintz Venture Capital & Emerging Companies team has remained incredibly busy, structuring and advising companies from term sheet to closing. For the first half of 2024, we completed 73 transactions, with an aggregate deal value in excess of $980 million.